Explore our featured news items here. Subscribe to stay informed of all information shared and published by OHC.
Sponsor appreciation:
You’re invited to explore and join Physician Factor, a knowledge exchange network is a dedicated portal for physicians seeking opportunities to contribute their expertise and input in exchange for compensation and supplemental income.
You can search articles using your own keywords or the following tags: Lung Cancer | Breast Cancer | Drugs and Therapies | Cancer General
Scientists Employ AI To Predict Brain Cancer Outcomes
Stanford Medicine scientists and colleagues create an algorithm that could help physicians better understand and target complicated brain tumors.
Expanding the Impact of CAR T Cell Therapy: An Immunotherapy Strategy Against All Blood Cancers
A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer. Scientists in the Perelman School of Medicine at the University of Pennsylvania have demonstrated the potential efficacy of this approach in preclinical tests.
A New Targeted Treatment Shows Promise for Select Patients with Stomach Cancer
An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and New York-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker. If approved, zolbetuximab will be the first targeted therapy in the U.S. for patients with previously untreated advanced gastric or esophageal junction cancer that is human epidermal growth factor receptor 2 (HER2)-negative and overexpresses the protein claudin-18 isoform 2 (CLDN 18.2).
THIO Followed by Cemiplimab Shows Early Promise in Advanced NSCLC
The sequential combination of THIO (6-thio-2’-deoxyguanosine) and cemiplimab (Libtayo) provided a progression-free survival (PFS) benefit in the first 2 patients with advanced non–small cell lung cancer (NSCLC) enrolled to the part A safety lead-in portion of the phase 2 THIO-101 trial (NCT05208944).
First Test Of Anti-Cancer Agent PAC-1 In Human Clinical Trials Shows Promise
A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. The drug stalled the growth of tumors in the five people in the trial with neuroendocrine cancers and reduced tumor size in two of those patients. It also showed some therapeutic activity against sarcomas, scientists and clinicians report in the British Journal of Cancer.
NCI Study Advances Personalized Immunotherapy For Metastatic Breast Cancer
An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research.
Early Cancer Therapeutics Group
The Early Cancer Therapeutics Group at Mayo Clinic offers patients whose cancers haven’t responded to standard chemotherapy or other treatments the opportunity to join an early-phase clinical trial of a potential new treatment.